Company intelligence / Profile preview

Cytocell

Cambridge, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Cytocell develops and commercially supplies a large portfolio (500+ catalogue probes) of fluorescence in situ hybridisation (FISH) probes for cytogenetics, haematology, solid tumour and rare disease applications, used globally in research and clinical laboratories.[3][6][10] As an in‑vitro diagnostics / research tools provider rather than a therapeutic developer, it does not run drug clinical trials.

Therapeutic areas: OncologyRare DiseasesHematology
Modalities: Non-pharmacological therapyDevice
Industry: Molecular Diagnostics

Partnerships

Oxford Gene Technology (integration into OGT genomic medicine portfolio)[2][6]Sysmex (distribution of Cytocell portfolio in selected markets such as China and Spain via Sysmex group channels)[8]

Beyond the preview

Go deeper on Cytocell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytocell.

Explore the full profile